ConductScience.org, home

Paper39607486

Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.

Zhao L and 9 others. Ann Hematol, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL. Papers, record 39607486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39607486

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
PubMed
Journal
Ann Hematol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2025-05-17
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhao LLinlin
2Sun LLili
3Kong DDesheng
4Cao RRongyi
5Guo ZZhibo
6Guo DDan
7Li QQi
8Hao JJiaLi
9Li YYinghua
10Emails LLi

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bridged Bicyclo Compounds, HeterocyclicMajor topic
AminopyridinesMajor topic
N-Myc Proto-Oncogene ProteinMajor topic
Wnt Signaling PathwayMajor topic
SulfonamidesMajor topic
BenzamidesMajor topic
Adaptor Proteins, Signal TransducingMajor topic
Precursor B-Cell Lymphoblastic Leukemia-LymphomaMajor topic
Intercellular Signaling Peptides and ProteinsMajor topic
Humans
Animals
Drug Synergism
Mice
Cell Line, Tumor
Antineoplastic Combined Chemotherapy Protocols
Histone Deacetylase Inhibitors
beta Catenin

Source PubMed

Download CSV of topics

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121941284A decade of exploring the cancer epigenome - biological and translational implications.Nat Rev Cancer2011https://conductscience.org/library/papers/21941284PubMed
233691573Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.Leuk Lymphoma2021https://conductscience.org/library/papers/33691573PubMed
328604239Continuing challenges and current issues in acute lymphoblastic leukemia.Leuk Lymphoma2018https://conductscience.org/library/papers/28604239PubMed
427343252Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Blood2016https://conductscience.org/library/papers/27343252PubMed
522682243Wnt/β-catenin signaling and disease.Cell2012https://conductscience.org/library/papers/22682243PubMed
633160401Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.Clin Epigenetics2020https://conductscience.org/library/papers/33160401PubMed
733566253Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.Invest New Drugs2021https://conductscience.org/library/papers/33566253PubMed
826766585Parsing Myc Paralogs in Oncogenesis.Cancer Cell2016https://conductscience.org/library/papers/26766585PubMed
927194046Epigenetic Determinants of Cancer.Cold Spring Harb Perspect Biol2016https://conductscience.org/library/papers/27194046PubMed
1031974619Chidamide induces necroptosis via regulation of c‑FLIPL expression in Jurkat and HUT‑78 cells.Mol Med Rep2020https://conductscience.org/library/papers/31974619PubMed
1132035785Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.Clin Lymphoma Myeloma Leuk2020https://conductscience.org/library/papers/32035785PubMed
1224334727MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.Oncotarget2014https://conductscience.org/library/papers/24334727PubMed
1325384499Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.Oncol Rep2015https://conductscience.org/library/papers/25384499PubMed
1424561519BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.Leukemia2014https://conductscience.org/library/papers/24561519PubMed
1534815635Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma.Chin J Cancer Res2021https://conductscience.org/library/papers/34815635PubMed
1618337604Epigenetics in cancer.N Engl J Med2008https://conductscience.org/library/papers/18337604PubMed
1723280764MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma.Mol Carcinog2014https://conductscience.org/library/papers/23280764PubMed
1819003969Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin.Int J Cancer2009https://conductscience.org/library/papers/19003969PubMed
1925843293SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.Cancer Lett2015https://conductscience.org/library/papers/25843293PubMed
2018239621Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells.Leukemia2008https://conductscience.org/library/papers/18239621PubMed

See all 43 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42194003Targeting the WNT/β-Catenin Pathway in Hematological Malignancies: From Molecular Pathogenesis to Emerging Therapeutic Strategies.Biomolecules2026https://conductscience.org/library/papers/42194003PubMed
42137457Diagnostic and therapeutic challenges of locally advanced colon cancer complicated with acute lymphoblastic leukemia: A case report.Oncol Lett2026https://conductscience.org/library/papers/42137457PubMed
42058597Class I HDAC inhibition enhances the stem-like memory properties of CRISPR-engineered CAR T cells in neuroblastoma.Mol Ther Oncol2026https://conductscience.org/library/papers/42058597PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
CTNNB11499PubTator's text mininghttps://conductscience.org/library/genes/1499NCBI Gene
DKK327122PubTator's text mininghttps://conductscience.org/library/genes/27122NCBI Gene
HDAC99734PubTator's text mininghttps://conductscience.org/library/genes/9734NCBI Gene
MYCN4613PubTator's text mininghttps://conductscience.org/library/genes/4613NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39607486

GET https://conductscience.org/api/papers/v1/39607486/references?page=2